A retrospective historical study evaluating the safe use of current antidepressants in cardiology practice


Cite item

Full Text

Abstract

Aim. To confirm the data available in the literature on the cardiac safety of antidepressants. Subjects and methods. The archival data of 146 case histories were retrospectively analyzed. A study sample consisted of 96 cardiac inpatients regularly taking an antidepressant for more than 3 days during treatment for the underlying cardiovascular disease. The safe use of antidepressants was evaluated in terms of initial electrocardiogram (ECG) QTc interval changes, systolic and diastolic blood pressures (BP) (SBP and DBP), heart rate (HR), and hemorrhagic complications. The data obtained over periods of 3- and 6-8 days were analyzed. Results. The sample showed no clinically significant ECG QTc interval changes when taking regularly antidepressants within 8 days. Analysis of the dynamics of BP and HR in patients receiving antidepressants revealed no statistically significant differences in these indicators before and 3 and 6-8 days after drug administration. No case of hemorrhagic complications was seen in the study group taking antidepressants. Conclusion. The investigation generally confirms the high cardiac safety of new-generation antidepressants within at least the first week of therapy. Noteworthy are the low daily drug dosages (relatively specified in the instructions) that are sufficient for most cardiac patients with depressive disorders and an additional factor for minimizing adverse reactions.

About the authors

S V Ivanov

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России; ФГБНУ «Научный центр психического здоровья»

Москва, Россия

B A Volel

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России; ФГБНУ «Научный центр психического здоровья»

Москва, Россия

E A Syrkina

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

E S Ternovaya

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

D V Troshina

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

M V Grubova

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

I A Tolkacheva

ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской Федерации

Москва, Россия

A N Rozhkov

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Москва, Россия

A N Simonov

ФГБНУ «Научный центр психического здоровья»

Москва, Россия

References

  1. Смулевич А.Б. Депрессии при психических и соматических заболеваниях. М.: МИА, 2015: 640.
  2. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894-1898. https://doi.org/10.1161/hc4101.097519
  3. Van den Brink RHS, Van Melle JP, Honig A, et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the myocardial infarction and depression-intervention trial (MIND-IT). Am Heart J 2002;144:219-225. https://doi.org/10.1067/mhj.2002.123580
  4. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701-709. https://doi.org/10.1001/jama.288.6.701
  5. Taylor CB, Youngblood ME, Catellier D, et al. ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62(7):792-798. https://doi.org/10.1001/archpsyc.62.7.792
  6. Jiang W, Krishnan KRR. Treatment of Depression in the Medically Ill. In: Ciraulo DA, Shader RI (eds.). Pharmacotherapy of Depression, Second Edition. LLC: Springer Science+Business Media, 2011:399-415.
  7. Kimmel, SE, Schelleman, H, Berlin, JA, Oslin, DW, Weinstein, RB, Kinman, JL, Lewis, JD. The effect of selective serotonin re‐uptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. British journal of clinical pharmacology. 2011;72(3):514-517. https://doi.org/10.1111/j.1365-2125.2011.04008.x
  8. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000;20:137-140.
  9. Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine — preliminary findings. Arch Gen Psychiatry. 2000;57(9):875-882. https://doi.org/10.1001/archpsyc.57.9.875
  10. Serebruany VL, Glassman AH, Malinin AI, et al. Sertraline AntiDepressant Heart Attack Randomized Trial Study Group. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003; 108:939-944. https://doi.org/10.1161/01.CIR.0000085163.21752.0A
  11. Rechlin T. The effects of psychopharmacological therapy on heart rate variation. Nervenarzt. 1995;66:678-685. (In. Ger.)
  12. Yeragani V.K., Pesce V., Jayaraman A., et al. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry. 2002;52:418-429. https://doi.org/10.1159/000066390
  13. Yeragani VK, Roose S, Mallavarapu M, et al. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology. 2002;46:125-135. https://doi.org/10.1016/S0006-3223(02)01394-X
  14. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Shores-Wilson. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. American journal of Psychiatry. 2006;163(1):28-40. https://doi.org/10.1176/appi.ajp.163.1.28
  15. Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2009; 18:512-518. https://doi.org/10.1002/pds.1746
  16. Astrom-Lilja C, Odeberg JM, Ekman E, Hagg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiology and Drug Safety. 2008;17:587-592. https://doi.org/10.1002/pds.1607
  17. Wenzel-Seifert K, Wittmann M, Haen E. Torsade de Pointes episodes under treatment with selective serotonin reuptake inhibitors. Pharmacopsychiatry. 2010;43:279-281.
  18. Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288.
  19. Mbaya P, Alam F, Ashim S, Bennett D. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol. 2007;22:129-133. https://doi.org/10.1002/hup.834
  20. Letsas K, Korantzopoulos P, Pappas L, et al. QT interval prolongation associated with venlafaxine administration. Int J Cardiol. 2006;109(1):116-117. https://doi.org/10.1016/j.ijcard.2005.03.065
  21. Wernicke J, Lledó A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007;30(5):437-455. https://doi.org/10.2165/00002018-200730050-00007
  22. Olié JP, Gourion D, Montagne A, et al. Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study. Neuropsychiatr Dis Treat. 2010;35(6):71-79. https://doi.org/10.1016/j.encep.2009.10.011
  23. Kamijima K, Hashimoto S, Nagayoshi E, Koyama T. Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression. Neuropsychiatr Dis Treat. 2013;9:555-565. https://doi.org/10.2147/NDT.S42915
  24. Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother. 2002;5(3):479-498. https://doi.org/10.1517/14656566.3.5.479
  25. Hla KK, Boyd O. Mianserin and complete heart block. Hum Toxicol. 1987;6(5):401-402.
  26. Haefeli WE, Schoenenberger RA, Scholer A. Recurrent ventricular fibrillation in mianserin intoxication. BMJ. 1991;302(6773):415-416.
  27. Newman B, Crome P. The clinical toxicology of mianserin hydrochloride. Vet Hum Toxicol. 1979;21(Suppl):60-62.
  28. Fagiolini A, Comandini A, Catena Dell’Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033-1049. https://doi.org/10.1007/s40263-012-0010-5
  29. Райский В.А. Психотропные средства в клинике внутренних болезней. М.: Медицина; 1988:288.
  30. Fiedler VB, Buchheim S, Nitz RE, Scholtholt J. Haemodynamic effects of pirlindole, a new tetracyclic antidepressant agent. Arzneimittelforschung. 1983;33(2):244-250.
  31. Зайцев В.П., Кольцова Т.И. Применение трициклических антидепрессантов при ишемической болезни сердца. Клин мед. 1980;6:30-35.
  32. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs. 2010;24(6):479-499. https://doi.org/10.2165/11534420-000000000-00000
  33. Donazzolo Y, Latreille M, Caillaud M-A, Mocaer E, Seguin L. Evaluation of the Effects of Therapeutic and Supratherapeutic Doses of Agomelatine on the QT/QTc Interval: A Phase I, Randomized, Double-blind, Placebo-controlled and Positive-controlled, Crossover Thorough QT/QTc Study Conducted in Healthy Volunteers. J Cardiovasc Pharmacol. 2014;64:440-451. https://doi.org/10.1097/FJC.0000000000000136
  34. Медведев В.Э., Епифанов А.В. Инновационный метод терапии депрессии у пациентов с ишемической болезнью сердца. Обозрение психиатрии и медицинской психологии имени ВМ Бехтерева. 2010;3:46-50.
  35. Стаценко М.Е., Шилина Н.Н., Туркина С.В. Эффективность применения Вальдоксана в восстановительном периоде инфаркта миокарда у пациентов с сахарным диабетом типа 2 и тревожно-депрессивными расстройствами. Психиатрия и психофармакотерапия. 2012;14(6):8-13.
  36. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277-285. https://doi.org/10.1081/CLT-120037428
  37. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol. 2007;64:192-197. https://doi.org/10.1111/j.1365-2125.2007.02849.x
  38. Service JA, Waring WS. QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin Toxicol (Phila). 2008;46:71-73. https://doi.org/10.1080/15563650701275322
  39. Van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med. 2009;54(3):404-408. https://doi.org/10.1016/j.annemergmed.2009.04.016
  40. Hawton K, Bergen H, Simkin S, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry. 2010;196(5):354-358. https://doi.org/10.1192/bjp.bp.109.070219
  41. Howland RH. A critical evaluation of the cardiac toxicity of citalopram: part 1. J Psychosoc Nurs Ment Health Serv. 2011;49(11):13-16. https://doi.org/10.3928/02793695-20111102-04
  42. Preskorn SH, Flockhart D. Guide to Psychiatric Drug Interactions. Primary Psychiatry. 2004;11(2):39-60.
  43. Малин Д.И. Побочное действие психотропных средств. Вузовская книга. 2000:208.
  44. Andrade C, Sandarsh S, Chethan KB, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71(12):1565-1575. https://doi.org/10.4088/JCP.09r05786blu
  45. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry. 2004;65 (12):1642-1653.
  46. Kharofa J, Sekar P, Haverbusch M, et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke. 2007;38(11):3049-51. https://doi.org/10.1161/STROKEAHA.107.491472
  47. van Walraven C., Mamdani M.M., Wells P.S., Williams J.I. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;22;323(7314):655-658. https://doi.org/10.1136/bmj.323.7314.655
  48. Castro VM, Gallagher PJ, Clements CC, et al. Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. BMJ Open. 2012;2(2):e000544. https://doi.org/10.1136/bmjopen-2011-000544
  49. Мосолов С.Н. Справочное руководство по психотропным и противоэпилептическим препаратам, разрешенным к применению в России. М, 2002:173.
  50. Andrade Ch, Sharma E. Serotonin reuptake inhibitors and risk of abnormal bleeding. In: Mago R. (ed.) Adverse effects of psychotropic treatments. Psychiatric Clinic of North America. 2016;39;3:413-426. https://doi.org/10.1016/j.psc.2016.04.010
  51. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;13;163(1):59-64. https://doi.org/10.1001/archinte.163.1.59
  52. Bazire S. Psychotropic Drug Directory. 2010. HealthComm UK Limited. 2011:552.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies